Small molecule · Inhibitor of voltage-gated sodium channel · developed by Hospira
Bupivacaine is an amide-type long-acting local anesthetic that reversibly binds sodium ion channels in neuronal membranes, inhibiting depolarization and nerve impulse conduction. It is used to produce local or regional anesthesia and postsurgical analgesia, and is studied in postoperative and acute pain.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 24, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05109312 | Phase 4 | Analgesia | Active not recruiting | HRTX |
| NCT03827291 | Phase 4 | Laparotomy | Completed | PCRX |
| NCT03705065 | Phase 4 | Postoperative Pain | Completed | HRTX |
| NCT04102267 | Phase 4 | Analgesia | Completed | HRTX |
| NCT02058303 | Phase 4 | Hand Injuries | Terminated | PCRX |
| NCT07212114 | Phase 3 | Total Ankle Arthroplasty | Recruiting | PCRX |
| NCT06350981 | Phase 2/3 | Back Pain | Enrolling by invitation | PCRX |
| NCT06077422 | Phase 2/3 | Pain, Postoperative | Enrolling by invitation | PCRX |
| NCT05157841 | Phase 3 | Bunionectomy | Completed | PCRX |
| NCT05171179 | Phase 3 | Mammaplasty | Completed | PCRX |
| NCT03974932 | Phase 3 | Analgesia | Completed | HRTX |
| NCT04911062 | Phase 2 | Post-Operative Pain | Completed | HRTX |
| NCT03011333 | Phase 2 | Postoperative Pain | Completed | HRTX |
| NCT04293809 | Phase 1 | Breast Augmentation | Completed | PCRX |
| NCT02982889 | Phase 1 | Acute Pain | Completed | LQDA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Back PainHeart DiseasesNarcotic UseOpioid UsePain, PostoperativePerioperative ComplicationPhysical StressPost Operative PainPostsurgical AnalgesiaSurgery-ComplicationsTotal Ankle ArthroplastyAcute PainAnalgesiaBreast Augmentation
Updated Nov 1, 2026.